Tina Marriott - 28 Dec 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
President and COO
Signature
/s/ Jonathan Golightly, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
28 Dec 2023
Net transactions value
-$76,174
Form type
4
Filing time
02 Jan 2024, 16:58:49 UTC
Previous filing
17 Nov 2023
Next filing
29 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Options Exercise $8,480 +8,000 +1.9% $1.06* 422,548 28 Dec 2023 Direct F1, F2
transaction RXRX Class A Common Stock Sale $84,654 -8,000 -1.9% $10.58 414,548 28 Dec 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Stock Option (Right to Buy) Options Exercise $0 -8,000 -1.5% $0.000000 512,000 28 Dec 2023 Class A Common Stock 8,000 $1.06 Direct F1, F5
holding RXRX Stock Option (Right to Buy) 434,122 28 Dec 2023 Class A Common Stock 0 $8.55 Direct F4
holding RXRX Stock Option (Right to Buy) 159,226 28 Dec 2023 Class A Common Stock 0 $11.40 Direct F6
holding RXRX Stock Option (Right to Buy) 4,784 28 Dec 2023 Class A Common Stock 0 $11.40 Direct
holding RXRX Stock Option (Right to Buy) 150,000 28 Dec 2023 Class A Common Stock 0 $2.48 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023.
F2 Includes 1,144 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on November 20, 2023.
F3 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.34 to $10.75 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F4 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F5 Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date.
F6 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F7 One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date.